Acesion Pharma (private company)

See something wrong or missing? Let us know
Offices:
Copenhagen
Category:
Biotech
Business model:
B2B
Investors:
we tracked 2 investors
You need an account to access this feature. Login or create one from here. (it takes 20 seconds)

Total investments received (USD) - we tracked 1 transaction

You need an account to access this feature. Login or create one from here. (it takes 20 seconds)

Acesion Pharma is developing safer drugs for treatments for atrial fibrillation (AF).

It was founded in 2011 with seed money from two Danish venture funds, Novo Seeds and SEED Capital. It also received €3.7M from the Wellcome Trust (UK).

AF is the most common type of cardiac arrhythmia and is characterized by an irregular and abnormally high frequency in the upper chambers of the heart, the atria. AF is associated with impaired quality of life, increased rate of hospitalization, and increased risk of stroke and death.

AF is often treated acutely with electrical shock to bring the heart back to its normal rhythm and existing drug therapies have limited efficacy and/or are often associated with risk of serious adverse effects. There is a great need for more efficacious and safer drugs for the medical treatment of AF.

Acesion Pharma is developing a small molecule-based acute treatment of AF, a program funded by the Wellcome Trust Ltd. Within this program Acesion Pharma expects to select a development candidate in 2015.

In addition, Acesion Pharma is developing a chronic treatment to prevent the recurrence of AF and maintain normal heart rhythm (maintenance therapy). The new investment from Novo Seeds and Broadview Ventures will specifically fund the development of the chronic treatment of AF, a program that has been supported to date with funding from the Danish government through the "Innovation Fund Denmark" initiative.

Companies with similar profile to Acesion Pharma:

CompanyCriteria
Denmark Antag Therapeutics
45%
  • Similar verticals: Biotech
  • Similar business models: B2B
  • At least one vc investor: Novo Seeds
  • Total raised in a similar range: 1M - 5M USD
Denmark Reapplix
45%
  • Similar verticals: Biotech
  • Similar business models: B2B
  • At least one vc investor: Novo Seeds
  • Total raised in a similar range: 1M - 5M USD
Denmark Biosyntia
45%
  • Similar verticals: Biotech
  • Similar business models: B2B
  • At least one vc investor: Novo Seeds
  • Total raised in a similar range: 1M - 5M USD
Sweden Scandinavian Real Hearts
43%
  • Similar verticals: Biotech
  • Similar business models: B2B
  • Total raised in a similar range: 1M - 5M USD
  • Minim one investor from outside Scandinavia: Yes
Finland BioMensio
43%
  • Similar verticals: Biotech
  • Similar business models: B2B
  • Total raised in a similar range: 1M - 5M USD
  • Minim one investor from outside Scandinavia: Yes
Finland Desentum
43%
  • Similar verticals: Biotech
  • Similar business models: B2B
  • Total raised in a similar range: 1M - 5M USD
  • Minim one investor from outside Scandinavia: Yes
Finland MetGen
43%
  • Similar verticals: Biotech
  • Similar business models: B2B
  • Total raised in a similar range: 1M - 5M USD
  • Minim one investor from outside Scandinavia: Yes
Sweden Merozyne Therapeutics
35%
  • Similar verticals: Biotech
  • Similar business models: B2B
  • At least one vc investor: Novo Seeds
Sweden AMRA
34%
  • Similar business models: B2B
  • At least one vc investor: Novo Seeds
  • Minim one investor from outside Scandinavia: Yes
Finland Optomed
33%
  • Similar verticals: Biotech
  • Similar business models: B2B
  • Minim one investor from outside Scandinavia: Yes
Norway Planktonic
33%
  • Similar verticals: Biotech
  • Similar business models: B2B
  • Total raised in a similar range: 1M - 5M USD
Denmark Oncology Venture
33%
  • Similar verticals: Biotech
  • Similar business models: B2B
  • Total raised in a similar range: 1M - 5M USD
Denmark BioModics
33%
  • Similar verticals: Biotech
  • Similar business models: B2B
  • Total raised in a similar range: 1M - 5M USD
Denmark Orphazyme
33%
  • Similar verticals: Biotech
  • Similar business models: B2B
  • Minim one investor from outside Scandinavia: Yes
Norway Cytovation
33%
  • Similar verticals: Biotech
  • Similar business models: B2B
  • Total raised in a similar range: 1M - 5M USD
Sweden Athera
33%
  • Similar verticals: Biotech
  • Similar business models: B2B
  • Total raised in a similar range: 1M - 5M USD
Sweden Monocl
33%
  • Similar verticals: Biotech
  • Similar business models: B2B
  • Total raised in a similar range: 1M - 5M USD
Norway BerGenBio
33%
  • Similar verticals: Biotech
  • Similar business models: B2B
  • Minim one investor from outside Scandinavia: Yes
Sweden OxThera
33%
  • Similar verticals: Biotech
  • Similar business models: B2B
  • Minim one investor from outside Scandinavia: Yes
Finland Mobidiag
33%
  • Similar verticals: Biotech
  • Similar business models: B2B
  • Total raised in a similar range: 1M - 5M USD